À¯¹æ¾ÏÁ¾¿¡¼ÀÇ ´Ù¾à¹° ³»¼º À¯ÀüÀÚ ´Ü¹éÁú P-Glycoprotein ¹ßÇô³à¿¡ ´ëÇÑ ¿¬±¸
Expression of Multidrug Resistance P-Glycoprotein in Breast Carcinoma
¼Ò¼Ó »ó¼¼Á¤º¸
°¼º½Ä
Á¶¼¼Çå/±è»ó¼ø/Á¤Áø¼÷/È«¼÷Èñ
KMID : 0360319940260060912
Abstract
In 38 women with breast carcinoma who had locally advanced cancer without distant metastasis, the expression of P-glycoprotein was evaluated, using JSB-1 monoclonal antibody by ABC-immunoperoxidase method, P-glycoprotein was detected in 35 of 38
tumor
samples(91.4%). Result were expressed in a semiguantitative manner, taking into account the number of positive tumor cells(N index) and the specific staining index(I index). The frequencies of higher expression(N+I+2 or I+3) were detected in 0%
of
grade, I, 33% of grade ¥±and 90.9% of grade ¥²in infiltrating duct carcinoma. Recurred cases were 4 out of 38(10.5%), of which 3 cases showed high histologic grade and more advanced stage with strong P-glycoprotein expression (N+I+3).
Strong P-glycoprotein-positive staining in a majority of tumor cells(N+/I+3) was significantly correlated with histologic group with poor prognosis high histologic grade and recurrence. Thus, the pretreatment evaluation of P-glycoprotein
expression
may
be of prognostic value in patients with locally advanced breast cancer. The possiblity that Mdrl enhances the invasiveness of cancer was suggested.
Å°¿öµå
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸